Table 4.
Incidence rate of hemorrhagic events
| Overall (n = 6306) | Apixaban initiators (n = 3106) | From warfarin (n = 2038) | From other NOACs (n = 1118) | P value for trenda | |
|---|---|---|---|---|---|
| Any hemorrhage | 480 (5.52) | 204 (5.03) | 179 (5.88) | 94 (5.98) | 0.127 |
| Major hemorrhage | 210 (2.36) | 86 (2.07) | 82 (2.63) | 40 (2.49) | 0.221 |
| Intracranial | 67 (0.75) | 31 (0.74) | 22 (0.70) | 13 (0.80) | 0.939 |
| Cerebral | 44 (0.49) | 21 (0.50) | 18 (0.57) | 5 (0.31) | 0.446 |
| Subarachnoid | 7 (0.08) | 2 (0.05) | 1 (0.03) | 4 (0.25) | NA |
| Chronic subdural | 9 (0.10) | 7 (0.17) | 1 (0.03) | 1 (0.06) | NA |
| Others | 8 (0.09) | 1 (0.02) | 2 (0.06) | 4 (0.25) | NA |
| Gastrointestinal | 90 (1.01) | 34 (0.82) | 37 (1.18) | 17 (1.05) | 0.232 |
Note: Number of patients (% per year).
Abbreviations: NA, not assessed due to lower event rates; NOACs, non‐vitamin K oral anticoagulants.
a
Comparison among three subgroups.